MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Atrial Septal Defects and Patent Foramen Ovale: Current Data Update
Primary clinical manifestations associated with PFO and ASD and their therapeutic implications.
By Marilena Di Salvo, MD; Marco Monte, MD; and Marco Barbanti, MD
Contemporary PCI and Structural Heart
By Rasha Al-Lamee, MD, and Rahul Sharma, MD
1-Month DAPT Approved in Europe for Abbott’s Xience Stent in Patients at High Bleeding Risk
April 6, 2021—Abbott announced its Xience stent has received CE Mark approval in Europe for shorter duration of dual antiplatelet therapy (DAPT) for patients at high bleeding risk (HBR).
CT Assessment Before TMVR
Moderator: Dee Dee Wang, MD, FACC, FASE, FSCCTPanel: Mayra Guerrero, MD, and Marco Barbanti, MD
High-Resolution Lesion Assessment With OCT
What every interventional cardiologist needs to know about this FDA-approved imaging modality.
By Sahil A. Parikh, MD, and Marco A. Costa, MD, PHD
Identification of Vulnerable Plaques
Various imaging methods allow evaluation in vivo.
By Daisuke Nakamura, MD; Setsu Nishino, MD, PhD; Guilherme F. Attizzani, MD; Hiram G. Bezerra, MD, PhD; and Marco A. Costa, MD, PhD
Use of IVUS for Coronary CTO Procedures
An update on the technology and use of IVUS in this challenging coronary niche.
By John E. Coletta, MD; Etsuo Tsuchikane, MD, PhD; Ravi Nair, MD; Daniel I. Simon, MD; and Marco A. Costa, MD, PhD
PRODIGY Questions 2-Year Duration of Dual-Antiplatelet Therapy After Stenting
August 30, 2011—The European Society of Cardiology (ESC) announced that 24-month data from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study) study were presented at its annual meeting in Paris, France.
An Interview With Rebecca T. Hahn, MD
Dr. Hahn shares insights from the SCOUT tricuspid regurgitation trial, various valvular regurgitation guidelines, the formation for the interventional echocardiography subspecialty, and much more.
ZEUS Study of Uncertain DES Candidates Presented
March 31, 2014—Medtronic, Inc. (Minneapolis, MN) announced that findings from the ZEUS study of the company’s Endeavor Sprint zotarolimus-eluting stent (ZES) in uncertain drug-eluting stent (DES) candidates were presented by ZEUS lead investigator Marco Valgimigli, MD, at ACC.14, the 63rd annual scientific session of the American College of Cardiology, held in Washington, DC.
First Patient Enrolled in Biotronik's BIOFLOW-DAPT Trial
May 6, 2020—Biotronik announced the enrollment of the first patient in the BIOFLOW-DAPT trial evaluating a dual-antiplatelet therapy (DAPT) regimen in a complex subgroup of patients undergoing percutaneous coronary intervention (PCI).
Highlights from EuroPCR
DES, COURAGE, and the Great Debate
Published ZEUS Findings Support Medtronic's Endeavor Sprint ZES in Uncertain DES Candidates
March 2, 2015—Investigators in the ZEUS study concluded that using the Endeavor Sprint stent (Medtronic plc) combined with an abbreviated, tailored dual-antiplatelet therapy (DAPT) regimen resulted in a lower risk of 1-year major adverse cardiovascular events in uncertain candidates for drug-eluting stent (DES) implantation compared to treatment with a bare-metal stent using a similar duration of DAPT.
Enrollment Begins in Biotronik's BIOVITESSE Trial
October 9, 2017—Biotronik announced the start of enrollment of the BIOVITESSE trial, a coronary stent trial to assess the safety and clinical performance of a new coronary stent in de novo coronary artery lesions.
Biotronik’s Orsiro Mission DES With Short DAPT Studied in BIOFLOW-DAPT
August 30, 2023—Biotronik announced that 1-year data from the BIOFLOW-DAPT study demonstrated noninferiority and a good safety profile for the company’s Orsiro Mission drug-eluting stent (DES) compared with the Resolute Onyx DES (Medtronic) in patients at high risk of bleeding receiving short dual antiplatelet therapy (DAPT) percutaneous coronary intervention (PCI).
Worldwide Trends in TAVR
By Ted E. Feldman, MD, MSCAI, FACC, FESC, and Bernard Prendergast, BMedSci, BM BS, MRCP, DM, FRCP, FESC
Chief Medical Editor's Page
Radial Refinement
By Ted E. Feldman, MD, FSCAI, Chief Medical Editor
Aortic and Mitral Valves
By Ted E. Feldman, MD, FSCAI
Appraising the Role of PFO Closure
A review of updated trial data, available devices, and application of patent foramen ovale closure.
By Krishna S. Kallakuri, MD, and Rajeev L. Narayan, MD
WhiteSwell’s eLym System Studied for Treating Acute Decompensated Heart Failure
March 6, 2024—WhiteSwell announced 6-month follow-up data on initial patients with acute decompensated heart failure (ADHF) treated in its ongoing DELTA-HF trial.
